Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Haleos LabsNSE:HALEOSLABS +1.98%72 Days Payable is 121.91 as of Mar. 2026, which is 16% above its 10-year median of 104.72. GuruFocus rates NSE:HALEOSLABS with a GF Score™ of 72/100 and a GF Value™ of ₹1,129.24 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 701 Biotechnology companies, Haleos Labs ranks worse than 53.07% on this metric.
The historical rank and industry rank for Haleos Labs's Days Payable or its related term are showing as below:
NSE:HALEOSLABS'
s Days Payable Range Over the Past 10 Years
Min: 84.75 Med: 104.72 Max: 135.32
Current: 98.81
During the past 11 years, Haleos Labs's highest Days Payable was 135.32. The lowest was 84.75. And the median was 104.72.
NSE:HALEOSLABS's Days Payable is ranked worse than 53.07% of 701
companies
in the Biotechnology industry
Industry Median: 112.84
vs NSE:HALEOSLABS: 98.81
Haleos Labs's Days Payable
increased
from Mar. 2025 (87.35) to Mar. 2026 (121.91).
It may suggest that Haleos Labsdelayed paying its suppliers.
Haleos Labs Days Payable Related Terms
Haleos Labs Days Payable Historical Data
* Premium members only.
The historical data trend for Haleos Labs's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:HALEOSLABS vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Haleos Labs's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Haleos Labs Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Haleos Labs's Days Payable distribution charts can be found below:
* The bar in red indicates where Haleos Labs's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Haleos Labs's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Haleos Labs (NSE:HALEOSLABS) has a Days Payable of 121.91 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Haleos Labs and its competitors. This is 16% above median its historical median of 104.72. Over the past decade, Haleos Labs' Days Payable has ranged from 84.75 to 135.32. According to the industry distribution chart, Haleos Labs ranks #372 out of 701 companies in the Biotechnology industry, placing it in the top 53.1%.
Is Haleos Labs' Days Payable too high?
Haleos Labs' current Days Payable of 121.91 is 16% above median its 10-year median of 104.72. Over the past 10 years, this metric has ranged from a low of 84.75 to a high of 135.32. The Biotechnology industry median Days Payable is 112.84. Haleos Labs' value of 121.91 is 8% above this industry median. Based on the distribution chart, Haleos Labs ranks #372 out of 701 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Haleos Labs has a GF Score™ of 72/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Haleos Labs' Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Haleos Labs ranks #372 out of 701 companies for Days Payable. This places Haleos Labs in the lower half of its industry. The industry median Days Payable is 112.84. Haleos Labs' value of 121.91 is 8% above this benchmark. Historically, Haleos Labs' own Days Payable has ranged from 84.75 to 135.32 over the past decade. While the company's 10-year median is 104.72 vs. the industry median of 112.84, Haleos Labs has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Haleos Labs's current Days Payable of 121.91 is 8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Haleos Labs and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Haleos Labs's current Days Payable is 121.91, which is 16% above median its own 10-year median of 104.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Haleos Labs stock overvalued right now?
Based on GuruFocus' analysis, Haleos Labs (NSE:HALEOSLABS) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹1,129.24, compared to a current price of ₹1,623.60 — trading 43.8% above its estimated fair value. The current Days Payable is 121.91, which is 16% above median its 10-year median of 104.72 and 8% above the Biotechnology industry median of 112.84. Haleos Labs' overall GF Score™ is 72/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Haleos Labs (NSE:HALEOSLABS), the current Days Payable is 121.91 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Haleos Labs (NSE:HALEOSLABS) Overvalued in 2026?
Based on GuruFocus' analysis, Haleos Labs stock appears to be overvalued.
The current stock price of ₹1,623.60 is trading 43.8% above its estimated GF Value™ of ₹1,129.24.
GuruFocus considers Haleos Labs to be Significantly Overvalued.
Key valuation signals for NSE:HALEOSLABS:
Days Payable: 121.91 (16% above median its 10-year median of 104.72)
GF Value™: ₹1,129.24 vs. price of ₹1,623.60 (43.8% above fair value)
Industry Position: 8% above the Biotechnology median (#372 of 701)
No single metric tells the full story. See the NSE:HALEOSLABS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Haleos Labs Ltd is engaged in the Business of manufacturing Active Pharmaceutical Ingredients (APIs) and its intermediates and sells its products in India as well as exports. The group sells its products in India and also exports it to other countries. Some of its API products are used in therapy as an Antiulcer, Antifungal, Anti Obesity, Anesthesia, and others. The company has manufacturing facilities at Kazipally and Jeedimetla and its Research and Development center at Sanatnagar in Hyderabad.
72GF Score
Get the complete analysis for NSE:HALEOSLABS
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:HALEOSLABS has been successfully added to your 
